<?xml version='1.0' encoding='utf-8'?>
<document id="25070091"><sentence text="Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol."><entity charOffset="36-59" id="DDI-PubMed.25070091.s1.e0" text="pyronaridine-artesunate" /><entity charOffset="64-74" id="DDI-PubMed.25070091.s1.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.25070091.s1.e0" e2="DDI-PubMed.25070091.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25070091.s1.e0" e2="DDI-PubMed.25070091.s1.e1" /></sentence><sentence text="The objectives of this study were to characterize any drug-drug interaction between the antimalarial Pyramax (pyronaridine-artesunate [PA]) and the CYP2D6 probe substrate metoprolol and to assess the safety of 60-day or 90-day PA redosing, particularly with regard to liver biochemistry parameters"><entity charOffset="171-181" id="DDI-PubMed.25070091.s2.e0" text="metoprolol" /></sentence><sentence text=" Healthy adult subjects were randomized to arm A (n = 26) or arm B (n = 30), with the arm A subjects administered 100 mg metoprolol tartrate in the first period, 100 mg metoprolol tartrate with the third of three daily doses of PA in the second period, and three daily doses of PA alone in the 90-day redosing period"><entity charOffset="121-140" id="DDI-PubMed.25070091.s3.e0" text="metoprolol tartrate" /><entity charOffset="169-188" id="DDI-PubMed.25070091.s3.e1" text="metoprolol tartrate" /><pair ddi="false" e1="DDI-PubMed.25070091.s3.e0" e2="DDI-PubMed.25070091.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25070091.s3.e0" e2="DDI-PubMed.25070091.s3.e1" /></sentence><sentence text=" The arm B subjects received the three-day PA regimen in the first period, with redosing of the regimen after 60 days in the second period" /><sentence text=" The noncompartmental pharmacokinetic parameters were computed for metoprolol, its metabolite alpha-hydroxymetoprolol, and pyronaridine"><entity charOffset="67-77" id="DDI-PubMed.25070091.s5.e0" text="metoprolol" /><entity charOffset="94-117" id="DDI-PubMed.25070091.s5.e1" text="alpha-hydroxymetoprolol" /><entity charOffset="123-135" id="DDI-PubMed.25070091.s5.e2" text="pyronaridine" /><pair ddi="false" e1="DDI-PubMed.25070091.s5.e0" e2="DDI-PubMed.25070091.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25070091.s5.e0" e2="DDI-PubMed.25070091.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25070091.s5.e0" e2="DDI-PubMed.25070091.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25070091.s5.e1" e2="DDI-PubMed.25070091.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25070091.s5.e1" e2="DDI-PubMed.25070091.s5.e2" /></sentence><sentence text=" The coadministration of metoprolol and PA was associated with an average 47"><entity charOffset="25-35" id="DDI-PubMed.25070091.s6.e0" text="metoprolol" /></sentence><sentence text="93% (90% confidence interval [CI], 30" /><sentence text="52, 67" /><sentence text="66) increase in the maximum concentration of metoprolol and a 25"><entity charOffset="45-55" id="DDI-PubMed.25070091.s9.e0" text="metoprolol" /></sentence><sentence text="60% (90% CI, 15" /><sentence text="78, 36" /><sentence text="25) increase in the metoprolol area under the concentration-time curve from time zero to the last quantifiable concentration obtained (AUC0-t); these increases most likely resulted from pyronaridine-mediated CYP2D6 inhibition"><entity charOffset="20-30" id="DDI-PubMed.25070091.s12.e0" text="metoprolol" /><entity charOffset="186-198" id="DDI-PubMed.25070091.s12.e1" text="pyronaridine" /><pair ddi="false" e1="DDI-PubMed.25070091.s12.e0" e2="DDI-PubMed.25070091.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25070091.s12.e0" e2="DDI-PubMed.25070091.s12.e1" /></sentence><sentence text=" No interaction effect of metoprolol with pyronaridine was apparent"><entity charOffset="26-36" id="DDI-PubMed.25070091.s13.e0" text="metoprolol" /><entity charOffset="42-54" id="DDI-PubMed.25070091.s13.e1" text="pyronaridine" /><pair ddi="false" e1="DDI-PubMed.25070091.s13.e0" e2="DDI-PubMed.25070091.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25070091.s13.e0" e2="DDI-PubMed.25070091.s13.e1" /></sentence><sentence text=" Following dosing with PA, some subjects experienced rises in liver function tests above the upper limit of normal during the first few days following PA administration" /><sentence text=" All such elevations resolved typically within 10 days, and up to 30 days at most" /><sentence text=" In subjects who were redosed, the incidences of alanine aminotransferase (ALT) or aspartate transaminase (AST) level elevations were similar on the first and second administrations, with no marked difference between the 60-day and 90-day redosing"><entity charOffset="49-56" id="DDI-PubMed.25070091.s16.e0" text="alanine" /><entity charOffset="83-92" id="DDI-PubMed.25070091.s16.e1" text="aspartate" /><pair ddi="false" e1="DDI-PubMed.25070091.s16.e0" e2="DDI-PubMed.25070091.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25070091.s16.e0" e2="DDI-PubMed.25070091.s16.e1" /></sentence><sentence text=" " /></document>